发明公开
US20230348582A1 NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
审中-公开
基本信息:
- 专利标题： NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
- 申请号：US18142242 申请日：2023-05-02
- 公开(公告)号：US20230348582A1 公开(公告)日：2023-11-02
- 发明人： Anette Henriksen , Thomas Nylandsted Krogh , Per J. Greisen , Thomas Egebjerg
- 申请人： Novo Nordisk A/S
- 申请人地址： DK Begsvaerd
- 专利权人： Novo Nordisk A/S
- 当前专利权人： Novo Nordisk A/S
- 当前专利权人地址： DK Begsvaerd
- 优先权： EP 171090.8 2022.05.02 EP 201248.6 2022.10.13
- 主分类号： C07K16/22
- IPC分类号： C07K16/22 ; A61P3/10
摘要：
The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.